Table 1.
Type of PTAs | Composition | Size | Irradiation conditions |
Cancer cell type | Combined therapy | Application | Ref. | |
---|---|---|---|---|---|---|---|---|
Wavelength | Power and time | |||||||
ICG | ICG@PLGA/ cancer cell membrane |
200.4 nm | 808 nm | 1.0 W cm−2, 5 min | MCF-7 cells | PTT | Breast cancer therapy | [36] |
PDA | Borate coordination polymer coated PDA/PEGylation DOX |
200.0 nm | 808 nm | 1.5 W cm−2, 10 min | MCF-7 cells | PTT/chemotherapy | Breast cancer therapy | [39] |
PPy | PPy/PVA | 46.0 nm | 808 nm | 6.0 W cm−2, 5 min | HeLa cells | PTT | Cervical cancer therapy | [41] |
Semiconducting polymer | PDCDT/PEG | 56.0 nm | 1064 nm | 1.0 W cm−2, 10 min | 4T1 cells | PTT | Breast cancer therapy | [45] |
Graphene | PEGylated Graphene | 10–50 nm | 808 nm | 2.0 W cm−2, 5 min | 4T1 cells | PTT | Breast cancer therapy | [50] |
rGO | PEGylated rGO | 18.8 nm | 808 nm | 15.3 W cm−2, 8 min | U87MG cells | PTT | Glioma therapy | [52] |
SWCNTs | SWCNT@ mesoporous silica/PEG/DOX | 15–25 nm (thickness) 100–300 nm (length) |
808 nm | 0.5 W cm−2, 20 min | 4T1 cells | PTT/chemotherapy | Breast cancer therapy | [56] |
Gold nanostars | Au nanostars coated BSA/MMP2/IR-780 iodide | 121.5 nm | 808 nm | 0.8 W cm−2, 5 min | A549 cells | PTT/PDT | Lung cancer therapy | [75] |
Gold nanocages | DOX loaded AuNC@HA | 50 nm | 808 nm | 1.0 W cm−2, 5 min | MDA-MB-231 cells | PTT/chemotherapy | Breast cancer therapy | [76] |
CuS | Flower-like CuS/PVP | 50 nm (thickness) 500–800 nm (length) |
980 nm | 0.51 W cm−2, 10 min | HeLa cells | PTT | Cervical cancer therapy | [84] |
MoS2 | MoS2-PEG/DOX | 50.0 nm | 808 nm | 0.56 W cm−2, 20 min | 4T1 cells | PTT/chemotherapy | Breast cancer therapy | [88] |
WS2 | Gd3+/WS2/PEG | 80.0 nm | 808 nm | 0.5 W cm−2, 10 min | 4T1 cells | PTT/radiotherapy | Breast cancer therapy | [91] |
Fe3O4 | Perfluorohexane @PLGA/Fe3O4 | 347 nm | 780–2800 nm | 1.5 W cm−2, 12 min | SKOV3 cells | PTT | Ovarian cancer therapy | [99] |
Fe3O4 nanorings | PEGylated Fe3O4 nanorings | 70 nm (outer diameter) | Magnetic field | 30 kA/m, 365 kHz, 10 min | 4T1 cells | Magnetic hyperthermia | Breast cancer therapy | [103] |
MoOx | PEGylated MoOx | 15–25 nm | 1064 nm | 0.6 W cm−2, 10 min | 4T1 cells | PTT/PDT | Breast cancer therapy | [105] |
BP nanoparticles |
PEGylated BP NPs | 3.2 ± 1.0 nm | 808 nm | 2.0 W cm−2, 5 min | 4T1 cells | PTT | Breast cancer therapy | [112] |
BP nanosheets | DOX loaded PEGylated BP NSs | 100 nm | 808 nm | 1.0 W cm−2, 10 min | HeLa cells | PTT/chemotherapy | Cervical cancer therapy | [117] |
Ti3C2 | Hyaluronic acid modified Ti3C2/DOX | 100 nm (lateral size) | 808 nm | 0.8 W cm−2, 10 min | HCT 116 cells | PTT/PDT/chemotherapy | Colon cancer therapy | [124] |
Zr-FeP MOF | PEGylated siRNA/Zr-FeP MOF | 210 nm (length) | 635 nm | 1.9 W cm−2, 5 min | MCF-7 cells | PTT/PDT | Breast cancer therapy | [126] |
Boron nanosheets | DOX loaded PEGylated B NSs | 250 nm (lateral size) 20 nm (thickness) |
808 nm | 1.0 W cm−2, 10 min | MCF-7 cells | PTT/chemotherapy | Breast cancer therapy | [128] |